HLN
Haleon plc
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · GB
$9.60
−2.64%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
10.3x
EV/EBITDA
7.7x
Market Cap
$42.22B
MomentumView details →
1D Return
−2.64%
YTD Return
−4.84%
RSI (14)
39.1
ValuationView details →
P/E (Fwd)
10.3x
EV/EBITDA
7.7x
Market Cap
$42.22B
RSI (14)
39.1
MomentumView details →
1D Return
−2.64%
YTD Return
−4.84%
SummaryUpdated Jun 1, 2026
Haleon plc (LSE:HLN) is a British multinational consumer healthcare company that was spun off from GlaxoSmithKline in July 2022, making it one of the world's largest standalone consumer healthcare companies. The company was formed through the demerger of GSK's consumer healthcare division, which had been built over decades through acquisitions and internal development. Headquartered in Brentford, United Kingdom, Haleon operates globally across North America, Europe, Middle East, Africa, Latin America, and Asia Pacific, managing a portfolio of well-established consumer health brands that reach millions of consumers daily.
Similar companies
Latest newsMore news →
Haleon secured improved shelf placement agreements with U.S. retailers Walmart and Target to increase product visibility and market share.2d agoHaleon's antacid brand ENO launched a new advertising campaign in India, 'Acidity ke kayi naam, ENO sab par kare kaam', to educate consumers about acidity-related symptoms.19d ago